Sutro Biopharma, Inc.

Sutro Biopharma, Inc.

Biotechnology Research

South San Francisco, California 10,554 followers

Changing the future of Oncology

About us

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Website
http://www.sutrobio.com
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
South San Francisco, California
Type
Public Company
Founded
2003

Locations

  • Primary

    111 Oyster Point Blvd

    South San Francisco, California 94080, US

    Get directions

Employees at Sutro Biopharma, Inc.

Updates

Similar pages

Browse jobs

Funding

Sutro Biopharma, Inc. 12 total rounds

Last Round

Post IPO equity

US$ 75.0M

See more info on crunchbase